Publications by authors named "J Tingleff"
Article Synopsis
- The study aimed to compare mortality rates between users of selective serotonin reuptake inhibitors (SSRIs) and non-users within 60 days after testing positive for SARS-CoV-2 in Denmark.
- Of the 286,447 individuals analyzed, SSRI users had a higher mortality rate (3.6%) compared to non-users (1.0%), with SSRI use associated with a 32% higher risk of death even after adjusting for factors like age and comorbidities.
- The findings suggest that SSRIs may not be effective for treating COVID-19 and indicate a need to reconsider their repurposing for this purpose, as their use appears to correlate with increased mortality.
Objectives: Elevated soluble urokinase Plasminogen Activator Receptor (suPAR) is a biomarker associated with adverse outcomes. We aimed to investigate the associations between plasma suPAR levels (testing the cut-offs ⩽4, 4-6, and ⩾6 ng/mL) with risk of 14-day mortality, and with the risk of mechanical ventilation in patients that tested positive for SARS-CoV-2.
Methods: Observational cohort study of patients presenting with symptoms of COVID-19 at Department of Emergency Medicine, Amager and Hvidovre Hospital, Denmark from March 19th, 2020 to April 3rd, 2020.
Background: Severe acute respiratory syndrome coronavirus 2 (The Covid-19 pandemic) strains health care capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory, can ease this burden. Elevated blood-soluble urokinase plasminogen activator receptor (suPAR) has previously been shown to be associated with risk of intubation in confirmed COVID-19 patients.
View Article and Find Full Text PDFArticle Synopsis
- AKI (acute kidney injury) is common in COVID-19 patients, and the role of the soluble urokinase plasminogen activator receptor (suPAR) in this condition is being investigated as a potential risk factor.
- In a study involving 352 hospitalized COVID-19 patients, higher suPAR levels were linked to a significantly increased risk of developing AKI and the need for dialysis.
- The findings suggest that monitoring suPAR levels at admission could help predict AKI outcomes in hospitalized COVID-19 patients, indicating its potential role in the disease's kidney-related complications.